Description Avastin® (bevacizumab) is a recombinant humanized antibody to vascular endothelial growth factor (VEGF). Avastin is designed to bind to and inhibit VEGF, a protein that plays a critical role in tumor angiogenesis (the formation of new blood vessels to the tumor).
Development Status Genentech is pursuing a broad late-stage clinical development program with Avastin, evaluating its potential use in multiple tumor types with a variety of chemotherapy regimens and in combination with other targeted therapies such as Tarceva, Herceptin, Rituxan, Apomab, Apo2L/TRAIL, and the Hedgehog Antagonist. Avastin is being studied worldwide in more than 450 clinical trials and in more than 30 different tumor types.
In 2008, we plan to submit a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for the potential treatment of first-line metastatic renal cell carcinoma and for the potential treatment of relapsed glioblastoma multiforme (an aggressive type of brain cancer).
Avastin is being developed in collaboration with F. Hoffmann-La Roche.
Approved Uses
- In February 2004, the FDA approved Avastin for use in combination with intravenous 5-Fluorouracil (5-FU)-based chemotherapy as a treatment for patients with first-line metastatic cancer of the colon or rectum.
- In June 2006, the FDA approved Avastin for use in combination with intravenous 5-FU-based chemotherapy for patients with second-line metastatic cancer of the colon or rectum.
- In October 2006, the FDA approved Avastin in combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer.
Read more about Avastin's approved use.
Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.
National Institutes of Health Website: www.clinicaltrials.gov
June 2008